Does Rallies show 13F holders for RARE?

Yes. Rallies tracks hedge fund and 13F ownership data for RARE, including fund names, share counts, latest tracked quarter, and position changes when available.

Is RARE research on Rallies investment advice?

No. Rallies provides research, data, and educational context for RARE. It does not provide personalized investment advice.

RARE (Ultragenyx Pharmaceutical Inc.) Stock Analysis - Hedge Fund Holdings

Ultragenyx Pharmaceutical Inc. (RARE) is a publicly traded Healthcare sector company. As of May 21, 2026, RARE trades at $24.00 with a market cap of $2.38B and a P/E ratio of -3.82. RARE moved +4.14% today. Year to date, RARE is +1.13%; over the trailing twelve months it is -37.43%. Its 52-week range spans $18.29 to $58.00. Analyst consensus is strong buy with an average price target of $48.86. Rallies surfaces RARE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns RARE stock?

Hedge funds tracked by Rallies that own RARE include Duquesne Family, Eisler Capital, Farallon Capital, and Bridgewater Associates. The latest tracked quarter is Mar 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Ultragenyx Pharmaceutical Inc..

RARE Key Metrics

Key financial metrics for RARE
Metric	Value
Price	$24.00
Market Cap	$2.38B
P/E Ratio	-3.82
EPS	$-6.10
Dividend Yield	0.00%
52-Week High	$58.00
52-Week Low	$18.29
Volume	1
Avg Volume	0
Revenue (TTM)	$669.71M
Net Income	$-608.92M
Gross Margin	0.00%

Top Hedge Funds Holding RARE

Duquesne Family holds 85.44K shares of RARE, changed +0.00% as of Mar 31, 2025.
Eisler Capital holds 19.91K shares of RARE, changed +30.15% as of Jun 30, 2024.
Farallon Capital holds 14.00K shares of RARE, changed +0.00% as of Sep 30, 2025.
Bridgewater Associates holds 10.63K shares of RARE, changed +0.00% as of Dec 31, 2023.

Latest RARE News

Ultragenyx Q1 Loss Widens as Crysvita Sales Falter, Evkeeza and Dojolvi Rise — May 6, 2026
Ultragenyx Secures FDA Acceptance for UX111 BLA With Sept. 19, 2026 PDUFA Date — Apr 2, 2026
Ultragenyx Buy Rating Reiterated while DTX301 Trial Reduces Ammonia, Stock Falls 3.46% — Mar 12, 2026
Ultragenyx’s DTX301 Achieves 18% Ammonia Reduction and 27% Scavenger Med Cut at Week 36 — Mar 12, 2026
FDA Accepts DTX401 Gene Therapy BLA for GSDIa with August PDUFA Date — Feb 23, 2026

Recent RARE Insider Trades

SULIMAN SHEHNAAZ sold 5.74K (~$144.19K) on May 18, 2026.
Crombez Eric sold 344 (~$8.59K) on May 5, 2026.
Horn Howard sold 4.68K (~$116.61K) on May 1, 2026.

RARE Analyst Consensus

15 analysts cover RARE: 0 strong buy, 13 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $48.86.

Common questions about RARE

Who owns RARE stock?: Hedge funds tracked by Rallies that own RARE include Duquesne Family, Eisler Capital, Farallon Capital, and Bridgewater Associates. The latest tracked quarter is Mar 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Ultragenyx Pharmaceutical Inc..
Does Rallies show 13F holders for RARE?: Yes. Rallies tracks hedge fund and 13F ownership data for RARE, including fund names, share counts, latest tracked quarter, and position changes when available.
Is RARE research on Rallies investment advice?: No. Rallies provides research, data, and educational context for RARE. It does not provide personalized investment advice.